Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2006

01-08-2006 | Article

Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock

Authors: Y. Heper, E. H. Akalın, R. Mıstık, S. Akgöz, O. Töre, G. Göral, B. Oral, F. Budak, S. Helvacı

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2006

Login to get access

Abstract

The diagnostic value of procalcitonin, C-reactive protein, tumor necrosis factor-alpha, and interleukin-10 levels in differentiating sepsis from severe sepsis and the prognostic value of these levels in predicting outcome were evaluated and compared in patients with community-acquired sepsis, severe sepsis, and septic shock in the first 72 h of admission to the hospital. Thirty-nine patients were included in the study. The severe sepsis and septic shock cases were combined in a single “severe sepsis” group, and all comparisons were made between the sepsis (n=21 patients) and the severe sepsis (n=18 patients) groups. Procalcitonin levels in the severe sepsis group were found to be significantly higher at all times of measurements within the first 72 h and were significantly higher at the 72nd hour in patients who died. Procalcitonin levels that remain elevated at the 72nd hour indicated a poor prognosis. C-reactive protein levels were not significantly different between the groups, nor were they indicative of prognosis. No significant differences in the levels of tumor necrosis factor-alpha were found between the sepsis and severe sepsis groups; however, levels were higher at the early stages (at admission and the 24th hour) in patients who died. Interleukin-10 levels were also higher in the severe sepsis group and significantly higher at all times of measurement in patients who died. When the diagnostic and prognostic values at admission were evaluated, procalcitonin and interleukin-10 levels were useful in discriminating between sepsis and severe sepsis, whereas tumor necrosis factor-alpha and interleukin-10 levels were useful in predicting which cases were likely to have a fatal outcome.
Literature
1.
go back to reference Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518PubMedCrossRef Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518PubMedCrossRef
2.
go back to reference Becker KL, Nylen ES, White JC, Müller B, Snider RH (2004) Procalcitonin and the calcitonin gene family of peptides in inflammation, infection and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 89:1512–1525PubMedCrossRef Becker KL, Nylen ES, White JC, Müller B, Snider RH (2004) Procalcitonin and the calcitonin gene family of peptides in inflammation, infection and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 89:1512–1525PubMedCrossRef
3.
go back to reference van Rossum AM, Wulkan RW, Ousdesluys-Murphy AM (2004) Procalcitonin as an early marker of infection in neonates and children. Lanset Infect Dis 4:620–630CrossRef van Rossum AM, Wulkan RW, Ousdesluys-Murphy AM (2004) Procalcitonin as an early marker of infection in neonates and children. Lanset Infect Dis 4:620–630CrossRef
4.
go back to reference Carrol ED, Thomson APJ, Hart CA (2002) Procalcitonin as a marker of sepsis. Int J Antimicrob Agents 20:1–9PubMedCrossRef Carrol ED, Thomson APJ, Hart CA (2002) Procalcitonin as a marker of sepsis. Int J Antimicrob Agents 20:1–9PubMedCrossRef
5.
go back to reference Whicher J, Bienvenu J, Monneret G (2001) Procalcitonin as an acute phase marker. Ann Clin Biochem 38:483–493PubMedCrossRef Whicher J, Bienvenu J, Monneret G (2001) Procalcitonin as an acute phase marker. Ann Clin Biochem 38:483–493PubMedCrossRef
6.
go back to reference Carlet J (1999) Rapid diagnostic methods in the detection of sepsis. Infect Dis Clin North Am 13:483–494PubMedCrossRef Carlet J (1999) Rapid diagnostic methods in the detection of sepsis. Infect Dis Clin North Am 13:483–494PubMedCrossRef
7.
go back to reference Gogos CA, Drosou E, Bassaris HP, Skoutelis A (2000) Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181:176–180PubMedCrossRef Gogos CA, Drosou E, Bassaris HP, Skoutelis A (2000) Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181:176–180PubMedCrossRef
8.
go back to reference Schröder J, Staubach KH, Zabel P, Stüber F, Kremer B (1999) Procalcitonin as a marker of severity in septic shock. Langenbeck’s Arch Surg 384:33–38CrossRef Schröder J, Staubach KH, Zabel P, Stüber F, Kremer B (1999) Procalcitonin as a marker of severity in septic shock. Langenbeck’s Arch Surg 384:33–38CrossRef
9.
go back to reference Balcı C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanoğlu B (2003) Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 7:85–90PubMedCrossRef Balcı C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanoğlu B (2003) Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 7:85–90PubMedCrossRef
10.
go back to reference Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. J Respir Crit Care Med 163:396–402 Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. J Respir Crit Care Med 163:396–402
11.
go back to reference Ruokonen E, Nousiainen T, Pulkki K, Takala J (1999) Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 18:283–285PubMedCrossRef Ruokonen E, Nousiainen T, Pulkki K, Takala J (1999) Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 18:283–285PubMedCrossRef
12.
go back to reference Chiesa C, Pellegrini G, Panero A, Osborn JF, Signore F, Assumma M et al (2003) C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antanatal and perinatal complication, and infection. Clin Chem 49:68–68CrossRef Chiesa C, Pellegrini G, Panero A, Osborn JF, Signore F, Assumma M et al (2003) C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antanatal and perinatal complication, and infection. Clin Chem 49:68–68CrossRef
13.
go back to reference Wunder C, Eichelbronner O, Roewer N (2004) Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II. Inflamm Res 53:158–163PubMedCrossRef Wunder C, Eichelbronner O, Roewer N (2004) Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II. Inflamm Res 53:158–163PubMedCrossRef
14.
go back to reference American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874CrossRef American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874CrossRef
15.
go back to reference Meisner M, Tschaikowsky K, Palmaers T, Schmidt J (1999) Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 3:45–50PubMedCrossRef Meisner M, Tschaikowsky K, Palmaers T, Schmidt J (1999) Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 3:45–50PubMedCrossRef
16.
go back to reference Müller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W et al (2000) Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 28:977–983PubMedCrossRef Müller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W et al (2000) Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 28:977–983PubMedCrossRef
17.
go back to reference Clec’h C, Ferriere F, Karoubi P, Fosse JP, Cupa M, Hoang P et al (2004) Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 32:1166–1169PubMedCrossRef Clec’h C, Ferriere F, Karoubi P, Fosse JP, Cupa M, Hoang P et al (2004) Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 32:1166–1169PubMedCrossRef
18.
go back to reference Ruokonen E, Ilkka L, Niskanen M, Takala J (2002) Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaestesiol Scand 46:398–404CrossRef Ruokonen E, Ilkka L, Niskanen M, Takala J (2002) Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaestesiol Scand 46:398–404CrossRef
19.
go back to reference Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent J (1999) Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 27:498–504PubMedCrossRef Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent J (1999) Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 27:498–504PubMedCrossRef
20.
go back to reference Müller B, Becker KL (2001) Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly 131:595–602PubMed Müller B, Becker KL (2001) Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly 131:595–602PubMed
21.
go back to reference Levy MM, Fink PM, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ATS/SIS International sepsis definitions conference. Crit Care 31:1250–1256CrossRef Levy MM, Fink PM, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ATS/SIS International sepsis definitions conference. Crit Care 31:1250–1256CrossRef
22.
go back to reference Monneret G, Finck ME, Venet F, Debard AL, Bohe J, Bienvenu J, Lepape A (2004) The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 95:193–198PubMedCrossRef Monneret G, Finck ME, Venet F, Debard AL, Bohe J, Bienvenu J, Lepape A (2004) The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 95:193–198PubMedCrossRef
23.
go back to reference Dinarello CA (1997) Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112:321–329CrossRef Dinarello CA (1997) Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112:321–329CrossRef
24.
go back to reference Stanilova SA, Karakolev ZT, Dimov GS, Dobreva ZG, Miteva LD, Slavov ES, Stefanov CS, Stanilov NS (2005) High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors. Intensive Care Med 31:401–407PubMedCrossRef Stanilova SA, Karakolev ZT, Dimov GS, Dobreva ZG, Miteva LD, Slavov ES, Stefanov CS, Stanilov NS (2005) High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors. Intensive Care Med 31:401–407PubMedCrossRef
25.
go back to reference Lowe PR, Galley HF, Abdel-Fattah A, Webster NR (2003) Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 31:34–38PubMedCrossRef Lowe PR, Galley HF, Abdel-Fattah A, Webster NR (2003) Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 31:34–38PubMedCrossRef
26.
go back to reference Loisa P, Rinne T, Laine S, Hurme M, Kaukinen S (2003) Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 47:319–325PubMedCrossRef Loisa P, Rinne T, Laine S, Hurme M, Kaukinen S (2003) Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 47:319–325PubMedCrossRef
27.
go back to reference Al-Nawas B, Kammer I, Shah PM (1996) Procalcitonin in diagnosis of severe infections. Eur J Med Res 1:331–333PubMed Al-Nawas B, Kammer I, Shah PM (1996) Procalcitonin in diagnosis of severe infections. Eur J Med Res 1:331–333PubMed
28.
go back to reference Kotake Y, Moore DR, Vasquez-Walden A, Tabatabaie T, Sang H (2003) Antioxidant amplifies antibiotic protection in the cecal ligation and puncture model of microbial sepsis through interleukin-10 production. Shock 19:252–256PubMedCrossRef Kotake Y, Moore DR, Vasquez-Walden A, Tabatabaie T, Sang H (2003) Antioxidant amplifies antibiotic protection in the cecal ligation and puncture model of microbial sepsis through interleukin-10 production. Shock 19:252–256PubMedCrossRef
29.
go back to reference Manley MO, O’Riordan MA, Levine AD, Latifi SQ (2005) Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome. Shock 23:521–526PubMed Manley MO, O’Riordan MA, Levine AD, Latifi SQ (2005) Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome. Shock 23:521–526PubMed
30.
go back to reference Latifi SQ, O’Riordan MA, Levine AD (2002) Interleukin-10 controls the onset of irreversible septic shock. Infect Immun 70:4441–4446PubMedCrossRef Latifi SQ, O’Riordan MA, Levine AD (2002) Interleukin-10 controls the onset of irreversible septic shock. Infect Immun 70:4441–4446PubMedCrossRef
31.
go back to reference Kahlke V, Dohm C, Mees T, Brotzmann K, Schreiber S, Schroder J (2002) Early interleukin-10 treatment improves survival and enhances immune function only in males after hemorrhage and subsequent sepsis. Shock 18:24–28PubMedCrossRef Kahlke V, Dohm C, Mees T, Brotzmann K, Schreiber S, Schroder J (2002) Early interleukin-10 treatment improves survival and enhances immune function only in males after hemorrhage and subsequent sepsis. Shock 18:24–28PubMedCrossRef
32.
Metadata
Title
Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock
Authors
Y. Heper
E. H. Akalın
R. Mıstık
S. Akgöz
O. Töre
G. Göral
B. Oral
F. Budak
S. Helvacı
Publication date
01-08-2006
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2006
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-006-0168-1

Other articles of this Issue 8/2006

European Journal of Clinical Microbiology & Infectious Diseases 8/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine